News

A new study will examine a treatment for patients with systemic mastocytosis with an associated hematologic neoplasm.

Imatinib is a treatment for patients with aggressive SM without the KIT D816V mutation or having unknown KIT mutational status.

A 100 mg dose reduced mast cell burden, alleviated debilitating symptoms and improved quality of life compared to placebo.

A new prognostic score confirmed that KIT Inhibitors improve outcomes in patients with advanced systemic mastocytosis (SM).

A new model accurately distinguished between advanced and indolent systemic mastocytosis using blood sample parameters.

Undiagnosed systemic mastocytosis (SM) led to bleeding complications in a patient with a peanut allergy reaction.

The study results challenge recommendations that people with systemic mastocytosis should avoid certain food and drugs entirely.

More than half of patients with indolent systemic mastocytosis reported mild or worse quality of life issues.

Mastocytosis increased the risk of venom-induced anaphylaxis, but food and drug allergies were often overreported.

The woman lived with abdominal pain for more than a decade before receiving a diagnosis of indolent systemic mastocytosis.